What Causes Low Pancreatic Elastase?

Low pancreatic elastase, measured as fecal elastase-1 (FE-1) in a stool sample, signals that the pancreas is not producing enough digestive enzymes. The causes range from chronic diseases that physically destroy pancreatic tissue to conditions that disrupt the signaling that tells the pancreas to secrete, and even to situations where the test result itself is misleading. Chronic pancreatitis is the most widely recognized culprit, but diabetes, surgery, autoimmune disease, aging, and several less obvious conditions can all drive levels below the diagnostic cutoff of 200 micrograms per gram of stool.

Chronic Pancreatitis and Pancreatic Damage

The most straightforward reason for low FE-1 is progressive destruction of the pancreas itself. In chronic pancreatitis, repeated bouts of inflammation gradually replace functioning enzyme-producing cells with scar tissue. A study of chronic pancreatitis patients found that about two-thirds had low stool elastase, and those low values tracked with visible structural changes on imaging: dilated ducts, shrunken (atrophic) tissue, and calcification of the gland.¹ Once enough of the pancreas is scarred, it simply cannot produce enough elastase or its other digestive enzymes. The process is not reversible, and the insufficiency tends to worsen over time.

Alcohol and tobacco are the most common drivers of chronic pancreatitis in adults, though one controlled study found that when researchers isolated tobacco exposure from alcohol use, smoking itself was associated with pancreatic insufficiency even after adjusting for drinking.² Alcohol, interestingly, did not independently predict insufficiency in that same analysis once tobacco was accounted for. This does not mean alcohol is safe for the pancreas; it is well established as a cause of pancreatitis. It does suggest that smoking may be an underappreciated factor in pancreatic decline.

Cystic Fibrosis

Cystic fibrosis (CF) is the textbook genetic cause of extremely low pancreatic elastase. About 85% of people with CF develop exocrine pancreatic insufficiency because thick, sticky mucus blocks the small ducts that carry digestive enzymes out of the pancreas. Over time, this blockage destroys the enzyme-producing cells and replaces them with fibrous tissue. In studies of children with CF, the vast majority had elastase levels that were essentially undetectable, often below 20 micrograms per gram, reflecting severe insufficiency.³ A small minority of CF patients retain some pancreatic function (called “pancreatic sufficient”), and their elastase readings can fluctuate. Research has shown that in pancreatic-sufficient CF patients, individual FE-1 values can vary by up to 35% between stool samples, which occasionally leads to a single borderline reading that crosses below the diagnostic cutoff even when the person is not truly insufficient.⁴

Pancreatic Cancer and Surgical Resection

Pancreatic tumors can block the main pancreatic duct or destroy enzyme-producing tissue as they grow. Among patients about to undergo surgery for various pancreatic or periampullary conditions, those with pancreatic cancer were far more likely to already have low elastase before surgery: roughly two-thirds of the cancer patients showed exocrine insufficiency preoperatively, compared to much smaller fractions for other diagnoses.⁵

Surgery to remove a pancreatic tumor then makes things worse. The Whipple procedure (pancreaticoduodenectomy), which removes the head of the pancreas along with part of the small intestine, is the most common operation for pancreatic head cancers. A prospective study of 29 patients found that about half had exocrine insufficiency at diagnosis; by six months after surgery, nearly all of them did.⁶ Distal pancreatectomy (removing the tail) can also lower elastase output, though often less dramatically because the head of the pancreas produces the bulk of digestive enzymes. Gastric surgery, even when the pancreas itself is not touched, can cause what is sometimes called “pancreaticocibal asynchrony,” a mismatch in timing between food arriving in the intestine and pancreatic enzymes being released.⁷

Diabetes and the Pancreas Connection

This one surprises most people. We tend to think of diabetes as a problem with insulin (the endocrine side of the pancreas) and pancreatic insufficiency as a problem with digestive enzymes (the exocrine side). But the two sides share blood supply, anatomy, and signaling molecules, so trouble on one side frequently spills over to the other.

A large multicenter study screening over 1,000 diabetic patients confirmed that both type 1 and type 2 diabetes are associated with high rates of exocrine pancreatic insufficiency. The risk was correlated with earlier onset of diabetes, longer disease duration, and lower body weight.⁸ A study of Indian diabetic patients put numbers on the prevalence: about 31% of those with type 1 and 29% with type 2 diabetes had fecal elastase below the cutoff, compared to only about 4% of non-diabetic controls.⁹

In type 1 diabetes specifically, the loss of exocrine function appears to start early and worsen over time. Research comparing people with new-onset type 1 diabetes, long-standing type 1 diabetes, and healthy controls found that FE-1 was lower in both diabetic groups, with the longest-standing cases showing the lowest enzyme levels.¹⁰ The reason likely involves the trophic (growth-supporting) effect that insulin has on nearby exocrine cells. When insulin-producing beta cells are destroyed by the autoimmune process of type 1 diabetes, the surrounding tissue loses that local support and gradually shrinks.

Autoimmune Pancreatitis

Autoimmune pancreatitis (AIP) is a distinct condition where the body’s immune system attacks the pancreas, causing it to swell and malfunction. It can look alarmingly like pancreatic cancer on imaging, and the distinction matters enormously because AIP responds to steroid treatment. Patients with AIP often have low fecal elastase at diagnosis, reflecting the inflammation-driven disruption of enzyme production. In one study of 21 AIP patients, fecal elastase increased significantly after steroid therapy.¹¹

A case report documented even more dramatic recovery: after four weeks of steroids, fecal elastase fully normalized, and imaging showed marked improvement in pancreatic swelling.¹² This stands in stark contrast to chronic pancreatitis, where structural damage is permanent. A more recent study found that improvement in exocrine function was most likely when the head of the pancreas was the main site of involvement, and that the average elastase level rose from about 64 to about 202 micrograms per gram after treatment, though this increase did not quite reach conventional statistical significance.¹³ The key point for anyone with AIP is that low elastase in this condition does not necessarily mean lifelong enzyme replacement; treatment of the underlying inflammation can restore function.

Celiac Disease and Inflammatory Bowel Disease

Low pancreatic elastase does not always mean the pancreas itself is damaged. Sometimes the problem is upstream, in the gut. In celiac disease, the immune reaction to gluten flattens the villi of the small intestine. Those villi normally release a hormone called cholecystokinin (CCK) when food arrives, and CCK is the primary signal that tells the pancreas to release its enzymes. When the villi are destroyed, CCK secretion drops, and the pancreas simply does not get the message to work. Research has confirmed that this is a functional problem: once the intestinal lining heals on a gluten-free diet, CCK levels and pancreatic secretion return to normal.¹⁴

Inflammatory bowel disease (IBD), including both Crohn’s disease and ulcerative colitis, also turns up low FE-1 readings fairly often. In a study of IBD patients, the odds of a low fecal elastase were about ten times higher than in healthy controls. Loose stools, frequent bowel movements, and prior bowel surgery all raised the risk further.¹⁵ At a six-month follow-up, elastase normalized in the majority of those patients, which suggests that much of the low reading was related to dilution from watery stool or transient gut dysfunction rather than permanent pancreatic damage. Persistent low values were linked to longer disease duration and a history of surgery.

Aging

The pancreas shrinks with age. Imaging studies show that pancreatic volume increases through childhood, plateaus between roughly 20 and 60 years, and then begins to decline. The tissue itself shows more fibrosis, less blood flow, and fewer functioning cells.¹⁶ A systematic review estimated that about 5% of people over 70 and 10% of those over 80 have fecal elastase below the insufficiency cutoff, with about 5% having severe insufficiency.

A separate study of people over 60 without known gastrointestinal disease or diabetes found an even higher rate: about 22% had FE-1 below 200 micrograms per gram. Elastase levels correlated negatively with age, meaning they dropped steadily as people got older, with significant drops after age 70.¹⁷ The discrepancy between the two figures (the systematic review’s 5-10% and the single study’s 22%) likely reflects differences in how strictly other conditions like occult diabetes were excluded. Either way, the practical implication is that a low elastase reading in someone over 70 does not automatically point to a hidden disease; normal aging can push values below the cutoff.

Heart Failure

This is one of the more recently appreciated causes. In chronic heart failure, the heart cannot pump enough blood to meet the body’s needs, and the pancreas is not spared from the consequences. Research has found that in patients hospitalized with congestive heart failure, more than half had fecal elastase values consistent with pancreatic insufficiency. The mechanism appears to involve reduced blood flow to the pancreas (ischemia) combined with shifts in the autonomic nervous system: higher sympathetic (“fight or flight”) activity and lower parasympathetic (“rest and digest”) activity, both of which suppress pancreatic secretion. The severity of heart failure correlates inversely with elastase levels, meaning worse cardiac function predicts worse pancreatic output.¹⁸ Each episode of acute decompensation may cause a further drop in exocrine function, resulting in a cumulative decline over time.

HIV Infection

People living with HIV show unexpectedly high rates of low pancreatic elastase. In one study, over half of HIV-infected patients had subnormal FE-1 values, while none of the healthy controls did. The average elastase in the HIV group was substantially lower than in controls.¹⁹ The reasons are likely multiple: direct viral effects on the pancreas, opportunistic infections involving the gland, medication side effects, and the chronic inflammatory state that accompanies poorly controlled HIV. For people with HIV who have unexplained weight loss, bloating, or fatty stools, pancreatic insufficiency is worth considering alongside the more commonly suspected causes of malabsorption.

Rare Genetic Conditions in Children

Beyond cystic fibrosis, a handful of rare inherited disorders cause low pancreatic elastase. Shwachman-Diamond syndrome is the second most common genetic cause of pancreatic insufficiency in children. It affects the pancreas, bone marrow, and skeleton, and can present with extremely low fecal elastase even in the absence of diarrhea or obvious malabsorption. Case reports have documented FE-1 levels below 15 micrograms per gram in children who had no gastrointestinal symptoms at all, which underscores that a normal stool pattern does not rule out severe pancreatic insufficiency in these conditions.²⁰

Premature Infants and Pancreatic Immaturity

Low fecal elastase in a newborn does not necessarily mean something is wrong. The pancreas begins producing enzymes during fetal development, but production is limited at birth: lipase output in a newborn is less than 10% of what an older child produces, and amylase is essentially absent. Elastase production ramps up over the first weeks and months of life.²¹

This is particularly relevant for premature babies. In extremely preterm infants (born before 28 weeks of gestation), elastase levels at two weeks of life are substantially lower than in babies born at 28 weeks or later. Elastase activity roughly doubles between week two and week four in these very early preemies, and by six weeks the gap between the two groups disappears.²² Clinicians who test a premature infant’s stool elastase too early may get a worrying result that simply reflects an immature pancreas rather than a disease process.

When the Test Itself Is Misleading

The fecal elastase test measures the concentration of enzyme in a stool sample. That means anything that dilutes the stool can artificially lower the result. Watery diarrhea is the biggest offender. A study examining paired samples from the same patients found that about 71% of low readings obtained from watery stool samples came back normal when a formed sample was tested instead.²³ This is an enormous false-positive rate, and it means that a single low reading on a loose or watery sample should be interpreted with real caution. Ideally, the test should be repeated on a formed stool before any firm diagnosis is made.

The test also has sensitivity limitations at the mild end of the spectrum. A meta-analysis found that fecal elastase-1 catches moderate and severe insufficiency well, with sensitivity around 96% when compared against fecal fat testing, but its sensitivity for mild insufficiency drops to roughly 63%.²⁴ A systematic review and meta-analysis estimated the overall pooled sensitivity at about 77% and specificity at about 88% compared to the secretin stimulation test, which is considered the gold standard.²⁵ The practical takeaway is that a normal elastase does not completely rule out mild insufficiency, and a low result on watery stool does not confirm it.

One reassuring detail for people already taking pancreatic enzyme replacement capsules (which contain porcine enzymes): the commercial FE-1 test specifically measures human elastase and does not cross-react with the porcine elastase found in replacement therapies. Patients on enzyme supplements do not need to stop them before testing, and the enzymes in the supplements will not inflate the result.⁴

Conditions That Reverse Versus Those That Do Not

Not all low elastase readings mean permanent insufficiency, and understanding which causes are reversible changes how aggressively you and your doctor need to act. In celiac disease, low elastase resolves with gluten avoidance as the intestinal lining regenerates and CCK signaling resumes. In autoimmune pancreatitis, steroid treatment can restore elastase to normal levels within weeks. In IBD, the majority of patients with low readings see values normalize over a few months, particularly if stool consistency improves. In premature infants, the pancreas simply catches up with time.

On the other end of the spectrum, chronic pancreatitis causes irreversible fibrosis, and elastase levels tend to decline further as more tissue is lost. Cystic fibrosis almost always results in lifelong severe insufficiency requiring enzyme replacement with every meal. Pancreatic surgery permanently removes tissue. And aging-related decline, while gradual, does not reverse. The distinction between functional and structural causes of low elastase is one of the most important pieces of context a clinician uses to decide whether a patient needs enzyme supplementation indefinitely or whether treating the underlying condition will restore pancreatic output on its own.